<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0050)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="aac"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC90851/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC90851_files/jig.min.css"><script type="text/javascript" src="./PMC90851_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Antimicrobial Agents and Chemotherapy"><meta name="citation_title" content="Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin"><meta name="citation_authors" content="Poe-Hirr Hsyu, Melissa D. Schultz-Smith, James H. Lillibridge, Ronald H. Lewis, Bradley M. Kerr"><meta name="citation_date" content="December 2001"><meta name="citation_issue" content="12"><meta name="citation_volume" content="45"><meta name="citation_firstpage" content="3445"><meta name="citation_doi" content="10.1128/AAC.45.12.3445-3450.2001"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC90851/?report=abstract"><meta name="citation_pmid" content="11709322"><meta name="DC.Title" content="Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="American Society for Microbiology (ASM)"><meta name="DC.Contributor" content="Poe-Hirr Hsyu"><meta name="DC.Contributor" content="Melissa D. Schultz-Smith"><meta name="DC.Contributor" content="James H. Lillibridge"><meta name="DC.Contributor" content="Ronald H. Lewis"><meta name="DC.Contributor" content="Bradley M. Kerr"><meta name="DC.Date" content="2001 Dec"><meta name="DC.Identifier" content="10.1128/AAC.45.12.3445-3450.2001"><meta name="DC.Language" content="en"><meta property="og:title" content="Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin"><meta property="og:type" content="article"><meta property="og:description" content="3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are effective agents in lowering cholesterol and triglycerides and are being used by human immunodeficiency virus-positive patients to treat the lipid elevation that may be associated ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC90851_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC90851_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC90851_files/common.min.js">//</script><script type="text/javascript" src="./PMC90851_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC90851_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC90851_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC90851_files/MathJax.js"></script><script type="text/javascript" src="./PMC90851_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-aac.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/pdf/ac1201003445.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="F4FB77F576C26061000000000011ED7B"><link type="text/css" rel="stylesheet" href="./PMC90851_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC90851_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC90851%2F&ncbi_pdid=article&ncbi_phid=F4FB77F576C26061000000000011ED7B'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC90851_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC90851%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC90851%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" style="visibility: hidden;"><img src="./PMC90851_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="archive-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/journals/82/">Antimicrob Agents Chemother</a></li><li class="issue-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/issues/2503/">v.45(12); 2001 Dec</a></li><li class="accid">PMC90851</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC90851_files/logo-aac.gif" alt="Logo of aac" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="321,60,397,75" alt="Permissions" title="Permissions" href="http://journals.asm.org/misc/reprints.dtl" ref="reftype=publisher&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="398,60,500,75" alt="Journals.ASM.org" title="Journals.ASM.org" href="http://journals.asm.org/" ref="reftype=publisher&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="0,0,500,55" alt="Journal" title="Journal" href="http://aac.asm.org/" ref="reftype=publisher&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="48,60,118,75" alt="AAC Article" title="AAC Article" href="http://aac.asm.org/cgi/content/full/45/12/3445" ref="reftype=publisher&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7CArticle%7CFullText&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="119,60,195,75" alt="Journal Info" title="Journal Info" href="http://aac.asm.org/misc/about.dtl" ref="reftype=publisher&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="195,60,251,75" alt="Authors" title="Authors" href="http://aac.asm.org/misc/authors.dtl" ref="reftype=publisher&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="252,60,318,75" alt="Reviewers" title="Reviewers" href="http://aac.asm.org/misc/reviewers.dtl" ref="reftype=publisher&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div><div><span class="cit">Antimicrob Agents Chemother. 2001 Dec; 45(12): 3445–3450. </span></div><div>  <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1128%2FAAC.45.12.3445-3450.2001" target="pmc_ext" ref="reftype=other&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1128/AAC.45.12.3445-3450.2001</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC90851</span></div></div></div></div></div><h1 class="content-title">Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Hsyu%20PH%5Bauth%5D">Poe-Hirr Hsyu</a>,<sup>*</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Schultz-Smith%20MD%5Bauth%5D">Melissa D. Schultz-Smith</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Lillibridge%20JH%5Bauth%5D">James H. Lillibridge</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Lewis%20RH%5Bauth%5D">Ronald H. Lewis</a>, and  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kerr%20BM%5Bauth%5D">Bradley M. Kerr</a></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id748532_ai" style="display:none"><div class="fm-affl" lang="en">Agouron Pharmaceuticals Inc., A Pfizer Company, La Jolla, California</div><div id="FN150"><sup>*</sup>Corresponding author. Mailing address: Agouron Pharmaceuticals Inc., A Pfizer Company, Clinical Pharmacology, 11085 Torreyana Rd., San Diego, CA 92121. Phone: (858) 622-7465. Fax: (858) 678-8293. E-mail: <a href="mailto:dev@null" data-email="moc.noruoga@uysh.eop" class="oemail">moc.noruoga@uysh.eop</a>.</div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" class="pmctoggle" rid="id748532_ai">Author information <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" class="pmctoggle" rid="id748532_an">Article notes <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" class="pmctoggle" rid="id748532_cpl">Copyright and License information <span>►</span></a></div><div class="fm-article-notes fm-panel hide half_rhythm" id="id748532_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2001 Jan 8; Revisions requested 2001 Jul 24; Accepted 2001 Sep 14.</div></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id748532_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a>  © 2001, American Society for Microbiology</div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>This article has been <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="__abstractid440270" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid440270title" style="text-transform: uppercase;">Abstract</h2><!--article-meta--><div><p id="__p2" class="p p-first-last">3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are effective agents in lowering cholesterol and triglycerides and are being used by human immunodeficiency virus-positive patients to treat the lipid elevation that may be associated with antiretroviral therapy. Many HMG-CoA reductase inhibitors and protease inhibitors are metabolized by the same cytochrome P450 enzyme 3A4 (CYP3A4). In addition, many protease inhibitors are potent inhibitors of CYP3A4. Therefore, coadministration of these two classes of drugs may cause significant drug interactions. This open-label, multiple-dose study was performed to determine the interactions between nelfinavir, a protease inhibitor, and two HMG-CoA reductase inhibitors, atorvastatin and simvastatin, in healthy volunteers. Thirty-two healthy subjects received either atorvastatin calcium (10 mg once a day) or simvastatin (20 mg once a day) for the first 14 days of the study. Nelfinavir (1,250 mg twice a day) was added on days 15 to 28. Pharmacokinetic assessment was performed on days 14 and 28. The study drugs were well tolerated. Nelfinavir increased the steady-state area under the plasma concentration-time curve during one dosing period (AUC<sub>τ</sub>) of atorvastatin 74% and the maximum concentration (<em>C</em><sub>max</sub>) of atorvastatin 122% and increased the AUC<sub>τ</sub> of simvastatin 505% and the <em>C</em><sub>max</sub> of simvastatin 517%. Neither atorvastatin nor simvastatin appeared to alter the pharmacokinetics of nelfinavir. It is recommended that coadministration of simvastatin with nelfinavir should be avoided, whereas atorvastatin should be used with nelfinavir with caution.</p></div></div><div id="__bodyid412294" class="tsec sec headless whole_rhythm"><p id="__p3" class="p p-first">The combination of a human immunodeficiency virus (HIV) protease inhibitor or a nonnucleoside reverse transcriptase inhibitor with two nucleoside reverse transcriptase inhibitors, so-called highly active antiretroviral therapy, is the recommended treatment for HIV-positive patients (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640322" role="button" aria-expanded="false" aria-haspopup="true">6</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B9" rid="B9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640307" role="button" aria-expanded="false" aria-haspopup="true">9</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640309" role="button" aria-expanded="false" aria-haspopup="true">22</a>). The adoption of highly active antiretroviral therapy has reduced the mortality and morbidity of HIV-positive patients dramatically (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640300" role="button" aria-expanded="false" aria-haspopup="true">14</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640324" role="button" aria-expanded="false" aria-haspopup="true">19</a>). However, with the long-term administration of these agents, metabolic changes such as hyperglycemia (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640312" role="button" aria-expanded="false" aria-haspopup="true">2</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_329115088" role="button" aria-expanded="false" aria-haspopup="true">8</a>), hyperlipidemia (M. J. Jimenez-Exposito, A. Paul, A Laville, and L. Masana, Abstr. 6th Eur. Conf. Clin. Aspect Treatment HIV Infect., 1997; package insert for Sustiva [efavirenz]), and lipodystrophy (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640318" role="button" aria-expanded="false" aria-haspopup="true">13</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B21" rid="B21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640320" role="button" aria-expanded="false" aria-haspopup="true">21</a>) have been observed in HIV-positive patients. The etiology of these changes is poorly understood. However, medications are prescribed to treat these metabolic changes because of concerns about the long-term cardiovascular risks. Lipid-lowering agents, especially HMG-CoA reductase inhibitors (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640305" role="button" aria-expanded="false" aria-haspopup="true">15</a>), are being used to reduce cholesterol and triglycerides in HIV-positive patients.</p><p id="__p4">Many HMG-CoA reductase inhibitors are metabolized by the liver cytochrome CYP3A4 enzyme. Coadministration of HMG-CoA reductase inhibitors with CYP3A4 inhibitors/substrates such as itraconazole (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640304" role="button" aria-expanded="false" aria-haspopup="true">16</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640325" role="button" aria-expanded="false" aria-haspopup="true">17</a>) and cyclosporine (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B1" rid="B1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640306" role="button" aria-expanded="false" aria-haspopup="true">1</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640323" role="button" aria-expanded="false" aria-haspopup="true">11</a>) significantly increases the levels of HMG-CoA reductase inhibitors in plasma. Simvastatin and lovastatin appear to be especially sensitive to P450 3A4 inhibition. For example, itraconazole increases the mean peak concentration and area under the concentration-time curve (AUC) of simvastatin and lovastatin approximately fivefold but increased the AUC of atorvastatin only 60% (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640316" role="button" aria-expanded="false" aria-haspopup="true">16</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640303" role="button" aria-expanded="false" aria-haspopup="true">17</a>). The greatly elevated concentrations of simvastatin and lovastatin caused by itraconazole or other CYP3A4 inhibitors may increase the risk of rhabdomyolysis (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640301" role="button" aria-expanded="false" aria-haspopup="true">18</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B20" rid="B20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640311" role="button" aria-expanded="false" aria-haspopup="true">20</a>; R. S. Lees and A. M. Lees, Letter, N. Engl. J. Med. <strong>333:</strong>664–665, 1995).</p><p id="__p5" class="p">All of the HIV protease inhibitors that are commercially available are metabolized by CYP3A4 and are inhibitors of CYP3A4. The dual protease inhibitor combination of saquinavir plus ritonavir has been shown to increase the concentration of simvastatin and atorvastatin (C. Fichtenbaum, J. Gerber, S. Rosenkranz et al., Abstr. 7th Conf. Retrovir. Opportunistic Infect., abstr LB 6, 2000). Nelfinavir, like the other protease inhibitors, is an inhibitor of CYP3A4, although it is not as strong a CYP3A4 inhibitor as ritonavir. Nelfinavir is a widely prescribed protease inhibitor. It is therefore important to study the interaction of nelfinavir and HMG-CoA reductase inhibitors. Two HMG-CoA reductase inhibitors were chosen for this study. Atorvastatin was studied because it is the most prescribed HMG-CoA reductase inhibitor, and simvastatin was studied because it is particularly susceptible to CYP3A4 inhibition.</p></div><div id="__sec1" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec1title" style="text-transform: uppercase;">MATERIALS AND METHODS</h2><div id="__sec2" class="sec sec-first"><p></p><h4 class="inline">Study design. </h4><p id="__p6" class="p p-first-last">This was an open-label, sequential, multiple-dose, single-center study to determine the pharmacokinetic interaction between nelfinavir and atorvastatin or nelfinavir and simvastatin in healthy volunteers. Thirty-two subjects were enrolled in the study. The study was performed at Phoenix International Life Sciences, Inc. (Neptune, N.J.).</p></div><div id="__sec3" class="sec"><p></p><h4 class="inline">Inclusion and exclusion criteria. </h4><p id="__p7" class="p p-first-last">Healthy male or female subjects 18 to 55 years old were enrolled after the Investigation Review Board approved the study protocol and subjects signed the informed consent form. Subjects were excluded if they took medications that might affect CYP3A4 activities, took alcohol or illegal drugs or smoked during the study, or were positive for HIV, hepatitis B, or hepatitis C.</p></div><div id="__sec4" class="sec"><p></p><h4 class="inline">Treatment. </h4><p id="__p8" class="p p-first-last">Subjects were divided into two groups. The two groups were roughly matched for gender, race, and age. The treatments were as follows.</p></div><div id="__sec5" class="sec"><p></p><h4 class="inline">Treatment group 1. </h4><p id="__p9" class="p p-first-last">In period 1<strong>,</strong> subjects received atorvastatin calcium (Lipitor; 10 mg once a day [QD]) in the morning for the first 14 days of the study. In period 2, subjects received atorvastatin calcium (10 mg QD) plus nelfinavir (Viracept; 1,250 mg twice a day [BID]) for an additional 14 days (days 15 to 28). All atorvastatin and nelfinavir doses were taken with food.</p></div><div id="__sec6" class="sec"><p></p><h4 class="inline">Treatment group 2. </h4><p id="__p10" class="p p-first-last">In period 1, subjects received simvastatin (Zocor; 20 mg QD) in the morning for the first 14 days of the study. In period 2, subjects received simvastatin (20 mg QD) plus nelfinavir (1,250 mg BID) for an additional 14 days (days 15 to 28). All simvastatin and nelfinavir doses were taken with food.</p></div><div id="__sec7" class="sec"><p></p><h4 class="inline">Pharmacokinetic sample collection. (i) Atorvastatin and simvastatin sample collections </h4><p id="__p11" class="p p-first-last">Trough samples (7 ml) were collected prior to dosing on days 1, 5, 10, 20, and 25. On days 14 and 28, serial blood samples (7 ml) were collected predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, and 24 h postdose.</p></div><div id="__sec8" class="sec"><p></p><h4 class="inline">(ii) Nelfinavir sample collections </h4><p id="__p12" class="p p-first-last">Trough samples (7 ml) were collected prior to initiation of nelfinavir on day 14 and prior to dosing on days 20 and 25. Serial blood samples (7 ml) were collected predose and at 1, 2, 3, 4, 5, 6, 8, 10, and 12 h postdose.</p></div><div id="__sec9" class="sec"><p></p><h4 class="inline">Bioanalytical procedures. (i) Nelfinavir and AG1402. </h4><p id="__p13" class="p p-first-last">Concentrations of nelfinavir and its active metabolite AG1402, previous named M8 (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640302" role="button" aria-expanded="false" aria-haspopup="true">25</a>), in plasma were measured by a validated reverse-phase high-performance liquid chromatography method with UV detection at PPD Development Inc. (Richmond, Va.). Plasma samples (0.25 ml) containing various concentrations of nelfinavir and AG1402 were mixed with an internal standard [6,7-dimethyl-2,3-di(2-pydridyl)-quinoxaline] solution (0.25 ml). Each sample was mixed with 0.5 ml of 0.1 N ammonium hydroxide (pH 10.5) and then extracted by 2.0 ml of ethyl acetate/acetonitrile (9:1 ratio) mixture. The mixture was centrifuged for 5 min at 1,000 × <em>g</em>, and the organic layer was transferred to a new tube and evaporated to dryness under a nitrogen stream at 50°C. The residue was reconstituted with 0.15 ml of mobile phase (25 mM sodium phosphate, monobasic pH 3.4, acetonitrile-methanol; 60:32.5:7.5 by volume) and subjected to high-performance liquid chromatography. Separation was achieved on a Waters symmetry C<sub>18</sub> column at 30°C with a flow rate of 1.5 ml and detection of nelfinavir and AG1402 via UV detection at 220 nm. The typical elution times of nelfinavir, AG1402, and the internal standard were 14.5, 6, and 11 min, respectively. This method was validated within a concentration range of 0.05 to 10.0 μg/ml for nelfinavir and AG1402. The standard curves were linear with <em>R</em><sup>2</sup> values of &gt;0.997. Nelfinavir and AG1402 were stable (&lt;20% loss from the baseline) for at least 21 months when stored at −20°C. The precision (percent coefficient of variation) of the assay for nelfinavir and AG1402 was ≤7.2 and 6.6%, respectively. The accuracy (deviation from the nominal concentrations) of the assay for nelfinavir and AG1402 was −16.0 to −6.6% and −5.9 to −1.7%, respectively.</p></div><div id="__sec10" class="sec"><p></p><h4 class="inline">(ii) Atorvastatin and simvastatin. </h4><p id="__p14" class="p p-first-last">Plasma samples were analyzed for atorvastatin equivalent concentrations (as the total of atorvastatin acid and its active metabolites) or simvastatin equivalent concentrations (as the total of simvastatin acid and its active metabolites) by a validated enzyme inhibition assay for HMG-CoA reductase inhibitors (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640299" role="button" aria-expanded="false" aria-haspopup="true">7</a>) at Phoenix International Life Sciences, Inc. (Saint-Laurent, Quebec, Canada). Atorvastatin or simvastatin was isolated from 0.25 ml of human plasma by protein precipitation with acetonitrile/acetone (95:5, vol/vol). The atorvastatin or simvastatin equivalent concentration was estimated by inhibition of the production of [<sup>14</sup>C]mevalone from [<sup>14</sup>C]HMG-CoA in the presence of HMG-CoA reductase from rat liver microsomes and cofactor. Since it was an enzyme inhibition assay, all of the atorvastatin or simvastatin and its active metabolites in plasma capable of inhibiting HMG-CoA reductase was quantified. Therefore, atorvastatin or simvastatin concentrations were expressed as atorvastatin or simvastatin equivalents. The standard curves were linear with <em>R</em><sup>2</sup> values of &gt;0.997 for both atorvastatin and simvastatin. This method was validated within concentration ranges of 0.18 to 7.35 ng/ml for atorvastatin and 0.3 to 15.2 ng/ml for simvastatin. The precision levels (percent coefficient of variation) of the assay for atorvastatin and simvastatin were ≤11.3 and 25.4%, respectively. The accuracy levels (deviation from the nominal concentrations) of the assay for atorvastatin and simvastatin were within 0.1 to 3.7% and −6.4 to 3.4%, respectively.</p></div><div id="__sec11" class="sec"><p></p><h4 class="inline">Safety evaluations. </h4><p id="__p15" class="p p-first-last">Adverse events and changes from the baseline laboratory parameters were monitored and evaluated. Metabolic laboratory parameters, including total cholesterol, low-density lipoproteins (LDL), triglycerides, glucose, insulin, and C-peptide, were determined after an overnight fast on screening, before first dosing, and on days 14 and 28.</p></div><div id="__sec12" class="sec sec-last"><p></p><h4 class="inline">Statistical analysis. </h4><p id="__p16" class="p p-first-last">Standard noncompartmental methods were used to calculate pharmacokinetic parameters. The geometric mean and its associated 95% confidence interval (CI) of the steady-state AUC during one dosing period (AUC<sub>τ</sub>) were calculated (time zero to 24 h postdose for atorvastatin and simvastatin and time zero to 12 h postdose for nelfinavir and AG1402). The geometric mean and its associated 95% CI of the <em>C</em><sub>max</sub> were calculated for atorvastatin, simvastatin, and nelfinavir. The ratio and its associated 90% CI of the geometric mean of the AUC<sub>τ</sub> and <em>C</em><sub>max</sub> of atorvastatin and simvastatin in the presence and absence of nelfinavir were also calculated. Analysis of variance was used to compare logarithmically transformed parameter values for atorvastatin and simvastatin in the absence and presence of nelfinavir, with the exception of <em>T</em><sub>max</sub>, which was analyzed by a nonparametric method. Pharmacokinetic parameters for nelfinavir and AG1402 were compared to results from previous studies with healthy volunteers who had taken nelfinavir (1,250 mg BID) for at least 10 days. Mean baseline values and percent changes in total cholesterol, LDL, and triglycerides on days 14 and 28 were calculated for each group.</p></div></div><div id="__sec13" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec13title" style="text-transform: uppercase;">RESULTS</h2><div id="__sec14" class="sec sec-first"><p></p><h4 class="inline">Demographic and baseline characteristics. </h4><p id="__p17" class="p p-first-last">The 32 enrolled subjects consisted of 12 Caucasians (six males and six females), 15 African Americans (eight males and seven females), and five Hispanics (two males and three females). One Caucasian male in treatment group 1 (atorvastatin and nelfinavir) developed a rash, requested withdrawal from the study, and was not included in the pharmacokinetic analysis. The mean (standard deviation [SD]) ages of the atorvastatin and simvastatin groups were 31.5 (5.0) and 38.3 (9.7) years, respectively. The mean (SD) body weights of the atorvastatin and simvastatin groups were 74 (12) and 72 (9) kg, respectively.</p></div><div id="__sec15" class="sec"><p></p><h4 class="inline">Pharmacokinetics. </h4><p id="__p18" class="p p-first">Mean (SD) trough atorvastatin equivalent concentrations on days 1, 5, 10, 14, 20, 25, and 28 were 0 (0.1), 1.5 (0.9), 2.4 (2.2), 2.0 (1.5), 2.2 (1.8), 3.7 (6.2), and 3.3 (3.3) ng-eq/ml, respectively. Mean (SD) trough simvastatin equivalent concentrations on days 1, 5, 10, 14, 20, 25, and 28 were 0 (0), 0.4 (0.3), 0.3 (0.3), 0.3 (0.4), 2.5 (2.9), 3.3 (8.7), and 2.3 (2.7) ng-eq/ml. These results indicated that the steady state of atorvastatin and simvastatin was reached on day 5 in period 1 and between days 20 to 25 in period 2. Mean trough concentrations of nelfinavir on days 15, 20, 25, and 28 were 0 (0), 2.4 (1.9), 3.0 (2.3), and 3.4 (2.0) ng-eq/ml, indicating that the steady state of nelfinavir was reached between days 20 and 35.</p><p id="__p19">The mean (SD) concentration-time profiles of atorvastatin in the absence and presence of nelfinavir are presented in Fig. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/figure/F1/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -2em;">Fig.1.</span></span><span>1</span></a>. Following the 14 days of atorvastatin dosing at 10 mg QD, the geometric mean AUC<sub>τ</sub> and <em>C</em><sub>max</sub> for atorvastatin equivalents (sum of atorvastatin acid and active metabolites) were 77 ng-eq·h/ml and 7.4 ng-eq/ml, respectively (Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). After the addition of nelfinavir at 1,250 mg BID to the atorvastatin regimen, the geometric mean steady-state AUC<sub>τ</sub> and <em>C</em><sub>max</sub> for atorvastatin equivalents were 134 ng-eq·h/ml and 16.4 ng-eq/ml, respectively (Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). These results represent increases of 74% in the AUC<sub>τ</sub> and 122% in the <em>C</em><sub>max</sub> after the addition of nelfinavir.    </p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><img src="./PMC90851_files/ac1210013001.gif" class="small-thumb" alt="FIG. 1" title="FIG. 1" src-large="/pmc/articles/PMC90851/bin/ac1210013001.jpg"></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">FIG. 1</a></div><!--caption a4--><div><span>Mean (SD) plasma concentration-time profiles of atorvastatin (ATOR) in the absence and presence of nelfinavir (NFV). eq., equivalents.</span></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/table/T1/" target="table" rid-ob="ob-T1" rid-figpopup="T1" class="table img_link icnblk_img figpopup"><img alt="TABLE 1" title="TABLE 1" class="small-thumb" src="./PMC90851_files/saved_resource" src-large="/pmc/articles/PMC90851/table/T1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/table/T1/" target="table" rid-figpopup="T1" rid-ob="ob-T1">TABLE 1</a></div><!--caption a4--><div><span>Pharmacokinetic parameters of atorvastatin and simvastatin<sup>a</sup> </span></div></div></div><p id="__p20">The mean (SD) concentration-time profiles of simvastatin in the absence and presence of nelfinavir are presented in Fig. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/figure/F2/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -2em;">Fig.2.</span></span><span>2</span></a>. Following the 14 days of simvastatin dosing at 20 mg QD, the geometric mean AUC<sub>τ</sub> and <em>C</em><sub>max</sub> for simvastatin equivalents (sum of simvastatin acid and active metabolites) were 42 ng-eq·h/ml and 7.4 ng-eq/ml, respectively (Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). After the addition of nelfinavir at 1,250 mg BID to the simvastatin regimen, the geometric mean AUC<sub>τ</sub> and <em>C</em><sub>max</sub> for simvastatin equivalents were 255 ng-eq·h/ml and 45.7 ng-eq/ml, respectively (Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). These results represent increases of 505% in the AUC<sub>τ</sub> and 517% in the <em>C</em><sub>max</sub> of simvastatin after the addition of nelfinavir.  </p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><img src="./PMC90851_files/ac1210013002.gif" class="small-thumb" alt="FIG. 2" title="FIG. 2" src-large="/pmc/articles/PMC90851/bin/ac1210013002.jpg"></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">FIG. 2</a></div><!--caption a4--><div><span>Mean (SD) plasma concentration-time profiles of simvastatin (SIM) in the absence and presence of nelfinavir (NFV). eq., equivalents.</span></div></div></div><p id="__p21" class="p p-last">The geometric means of the AUC<sub>τ</sub> (time zero to 12 h postdose) and <em>C</em><sub>max</sub> of nelfinavir in the presence of atorvastatin were 44 (95% CI, 35 to 54) μg·h/ml and 5.7 (95% CI, 4.8 to 6.8) μg/ml, respectively. The geometric mean of the AUC<sub>τ</sub> and <em>C</em><sub>max</sub> of nelfinavir in the presence of simvastatin were 38 (range, 31 to 47) μg·h/ml and 5.1 (95% CI, 4.3 to 6.1) μg/ml, respectively. The median <em>T</em><sub>max</sub> values of nelfinavir in the presence of atorvastatin and simvastatin were 5.0 (range, 2.0 to 8.0) and 5.0 (range, 2.0 to 6.0) h, respectively. The geometric mean ratios of the AG1402 AUC<sub>τ</sub> to the nelfinavir AUC<sub>τ</sub> were 0.35 (95% CI, 0.25 to 0.48) and 0.31 (95% CI, 0.22 to 0.42) in the presence of atorvastatin and simvastatin, respectively. There was no difference in the AUC<sub>τ</sub>, the <em>C</em><sub>max</sub>, the <em>T</em><sub>max</sub>, or the ratio of the AG1402 AUC<sub>τ</sub> to the nelfinavir AUC<sub>τ</sub> between these two groups (<em>P</em> &gt; 0.05).</p></div><div id="__sec16" class="sec sec-last"><p></p><h4 class="inline">Safety. </h4><p id="__p22" class="p p-first">Nelfinavir in combination with atorvastatin or simvastatin was well tolerated in this study. There were no serious adverse events. Twenty-seven subjects reported 64 adverse events. Thirty-eight (reported by 22 subjects) of the 64 adverse events were considered treatment-related adverse events, most related to nelfinavir treatment. The most frequently reported adverse event was diarrhea (reported by 17 subjects [53%]). Two grade 3 treatment-related adverse events (rash and migraine headache) were reported. Subject 3 had a severe rash on day 23 and withdrew from the study. Subject 3 was treated with Benadryl and prednisone orally plus Kenalog intramuscularly. The rash resolved after 13 days. Subject 14 experienced a severe migraine headache, which was treated with Tylenol and resolved after 2 days. Seven subjects received medications other than the study drugs. None of the medications were expected to have drug interactions with the study drugs.</p><p id="__p23" class="p p-last">Fasting cholesterol and LDL levels were significantly reduced in both arms on days 14 and 28 (Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/table/T2/" target="true" class="fig-table-link table figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -3em;">(Table2).</span></span><span>2</span></a>). Triglyceride levels were very variable, with the standard deviations typically greater than the mean values. Thus, the change from the baseline could not be assessed with confidence. Other metabolic parameters, including glucose, insulin, and C-peptide, were generally within the normal range and showed no consistent change from the baseline. No consistently elevated creatine phosphokinase (CPK) values, an early indicator of rhabdomyolysis, were observed. None of the elevated CPK values were greater than threefold higher than the upper limit of the normal range. Four subjects had four CPK values between two- and threefold higher than the upper limit of the normal range. Three of these high CPK values were baseline values, suggesting that these high CPK values were not treatment related. CPK values tended to stay the same or become lower during the study period.  </p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T2"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/table/T2/" target="table" rid-ob="ob-T2" rid-figpopup="T2" class="table img_link icnblk_img figpopup"><img alt="TABLE 2" title="TABLE 2" class="small-thumb" src="./PMC90851_files/saved_resource(1)" src-large="/pmc/articles/PMC90851/table/T2/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/table/T2/" target="table" rid-figpopup="T2" rid-ob="ob-T2">TABLE 2</a></div><!--caption a4--><div><span>Percent changes in lipid levels from baseline<sup>a</sup> </span></div></div></div></div></div><div id="__sec17" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec17title" style="text-transform: uppercase;">DISCUSSION</h2><p id="__p24" class="p p-first">HIV-positive patients usually take multiple medications, and therefore, drug interaction between these medications is an important issue for antiretroviral therapies. Many of these drugs can interact with each other in drug absorption, distribution, metabolism, and elimination. To achieve optimal dosing regimens for HIV-positive patients, it is important to understand the drug interaction between the medications. In this study, we investigated the interaction between nelfinavir and two HMG-CoA reductase inhibitors, simvastatin and atorvastatin, because of the potential for drug interaction and the potential of the coadministration of these drugs. Both simvastatin and atorvastatin are extensively metabolized by humans, and a number of active and inactive metabolites are produced. The active metabolites account for most of the activity of atorvastatin and simvastatin. The enzyme inhibition assay used in this study measured the total active HMG-CoA reductase inhibitors.</p><p id="__p25">The results of this study indicate that administration of 1,250 mg of nelfinavir BID increases the steady-state simvastatin equivalent concentrations extensively and increases the steady-state atorvastatin equivalent concentrations moderately. The geometric mean AUC<sub>τ</sub> and <em>C</em><sub>max</sub> of simvastatin-associated HMG-CoA inhibitors increased 505 and 517%, respectively, with the coadministration of nelfinavir. All of the subjects in the simvastatin arm showed an increase in the simvastatin equivalent AUC<sub>τ</sub> in the presence of nelfinavir, with a range of 145 to 1,524% (Fig. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/figure/F3/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.3),</span></span><span>3</span></a>), suggesting a consistent inhibitory effect of nelfinavir on simvastatin metabolism. Two subjects had a greater than 10-fold increase in the simvastatin AUC, and they also had the greatest nelfinavir AUCs (78 and 104 μg·h/ml, respectively), suggesting that the magnitude of the increase in simvastatin levels was related to the levels of nelfinavir in plasma. Linear regression of the simvastatin AUC ratio (the ratio of the AUC of simvastatin plus nelfinavir to that of simvastatin alone) versus the nelfinavir AUC in the individual subjects also demonstrated a high correlation between the simvastatin AUC ratio and the nelfinavir AUC with an <em>R</em><sup>2</sup> value of 0.81. Other factors, such as the simvastatin AUC in the absence of nelfinavir, gender, and race, were not related to the simvastatin AUC ratio. These results suggested that the nelfinavir level was a major determinant of the change in simvastatin levels. In contrast, the geometric mean AUC<sub>τ</sub> and <em>C</em><sub>max</sub> of atorvastatin-associated HMG-CoA inhibitors increased only 74 and 122%, respectively, with the coadministration of nelfinavir. Fourteen of the 15 subjects in the atorvastatin arm showed an increase in the AUC<sub>τ</sub> of atorvastatin equivalents in the presence of nelfinavir, with a range of −3 to 361% (Fig. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/figure/F3/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -2.5em;">(Fig.3),</span></span><span>3</span></a>), suggesting a fairly consistent inhibitory effect of nelfinavir on atorvastatin metabolism. Two subjects had a greater-than-threefold increase in atorvastatin. However, the AUCs of nelfinavir (42 and 60 μg·h/ml, respectively) in these two subjects were not particularly high, suggesting that the magnitude of the increase in atorvastatin levels was not related to the levels of nelfinavir in plasma. Factors such as the nelfinavir AUC, the atorvastatin AUC in the absence of nelfinavir, gender, and race were not related to the atorvastatin AUC ratio. The difference in the inhibitory effects of nelfinavir on simvastatin and atorvastatin was not unexpected. Simvastatin appears to be very sensitive to CYP3A4 inhibitors. Itraconazole, a classical CYP3A4 inhibitor, also increased the AUC and <em>C</em><sub>max</sub> of simvastatin equivalents markedly, whereas itraconazole had only a moderate effect on atorvastatin equivalents (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640313" role="button" aria-expanded="false" aria-haspopup="true">16</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640315" role="button" aria-expanded="false" aria-haspopup="true">17</a>). This difference may be explained by the different roles of CYP3A4 in their biotransformation (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B3" rid="B3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640310" role="button" aria-expanded="false" aria-haspopup="true">3</a>).  </p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><img src="./PMC90851_files/ac1210013003.gif" class="small-thumb" alt="FIG. 3" title="FIG. 3" src-large="/pmc/articles/PMC90851/bin/ac1210013003.jpg"></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">FIG. 3</a></div><!--caption a4--><div><span>(Left) Comparative plot of atorvastatin AUC<sub>τ</sub> values in the absence and presence of nelfinavir. (Right) Comparative plot of simvastatin AUC<sub>τ</sub> values in the absence and presence of nelfinavir</span></div></div></div><p id="__p26">The interaction between nelfinavir and simvastatin or atorvastatin is likely due mainly to the inhibition of CYP3A4 by nelfinavir since the in vitro and in vivo drug metabolism of these compounds is well established. Inhibition of CYP3A4 by nelfinavir could occur at the gastrointestinal wall, which would have a major effect on the bioavailability of simvastatin and atorvastatin, and/or at the liver, which would have an effect on the bioavailability and elimination rate of simvastatin and atorvastatin. In addition, a number of in vitro (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B4" rid="B4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640321" role="button" aria-expanded="false" aria-haspopup="true">4</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640308" role="button" aria-expanded="false" aria-haspopup="true">10</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_329115089" role="button" aria-expanded="false" aria-haspopup="true">23</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_329115090" role="button" aria-expanded="false" aria-haspopup="true">24</a>) and in vivo (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B5" rid="B5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640314" role="button" aria-expanded="false" aria-haspopup="true">5</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_99640317" role="button" aria-expanded="false" aria-haspopup="true">10</a>) studies have suggested that nelfinavir, atorvastatin, and simvastatin may also be substrates/inhibitors of the efflux pump P-glycoprotein. Inhibition of P-glycoprotein by nelfinavir may increase the oral absorption of atorvastatin and simvastatin and contribute to the observed clinical interaction. However, it is difficult to distinguish these mechanisms from this study, as it was designed to detect pharmacokinetic changes and not mechanisms of interaction.</p><p id="__p27">The active site of action of HMG-CoA reductase inhibitors is the liver. The concentrations of orally administered drugs in the liver tended to be much higher than their concentrations in plasma, especially during the absorption period. The increase in the systemic concentrations of atorvastatin and simvastatin caused by the coadministration of nelfinavir may not reflect the change in drug concentrations in the liver. It was interesting to observe similar cholesterol-lowering effects of atorvastatin and simvastatin in the presence and absence of nelfinavir (Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/table/T2/" target="true" class="fig-table-link table figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -3em;">(Table2)</span></span><span>2</span></a>) despite a significant increase in the systemic exposure of atorvastatin and simvastatin. These results may suggest different effects of nelfinavir on the systemic and liver pharmacokinetics of atorvastatin and simvastatin.</p><p id="__p28">No significant CPK elevation or rhabdomyolysis was observed in this small, short-term study. The safety results of this study, while reassuring, are difficult to extrapolate to chronic coadministration of atorvastatin or simvastatin with nelfinavir in HIV-positive patients. The greater-than-500% increase in the simvastatin concentration in the presence of nelfinavir was quite extensive and may increase the risk of skeletal muscle damage. Therefore, it is recommended that simvastatin not be coadministered with nelfinavir. Nelfinavir had a more moderate effect on atorvastatin concentrations. The recommended doses of atorvastatin are 10 to 80 mg/day. Thus, the 10-mg dose of atorvastatin should be started and titrated with caution to achieve the desired effect when coadministered with nelfinavir.</p><p id="__p29">In previous studies, the AUC<sub>τ</sub> and <em>C</em><sub>max</sub> of nelfinavir after administration of 1,250 mg BID to healthy volunteers ranged from 25 to 40 μg·h/ml and from 4 to 6 μg/ml (Agouron database), respectively, and the ratio of the AG1402 AUC<sub>τ</sub> to the nelfinavir AUC<sub>τ</sub> ranged from 0.2 to 0.4. The pharmacokinetic parameters of nelfinavir and AG1402 in this study were similar to those in a previous studies with healthy volunteers, suggesting that atorvastatin and simvastatin did not alter the pharmacokinetics of nelfinavir and its active metabolite. These results were not unexpected, as atorvastatin and simvastatin are weak CYP3A4 inhibitors and their concentrations were much lower than those of nelfinavir and AG1402.</p><p id="__p30" class="p p-last">In conclusion, a clinical dose of nelfinavir (1,250 mg BID) increased systemic exposure to simvastatin approximately 500% and is not recommended for long-term coadministration with simvastatin. Nelfinavir also increased systemic exposure to atorvastatin moderately and should be coadministered with atorvastatin with caution.</p></div><div id="__ackid1089299" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ackid1089299title" style="text-transform: uppercase;">ACKNOWLEDGMENTS</h2><div class="sec"><p id="__p40">We thank Gary Hutton, Statistical Associates, Inc., for excellent statistical analysis of the data and the Pfizer Atorvastatin Team for valuable suggestions for the study.</p></div></div><div id="__ref-listid1089309" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid1089309title" style="text-transform: uppercase;">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1">1. <span class="citation">Arnadottir M, Eriksson L O, Thysell H, Karkas J D. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. <span><span class="ref-journal">Nephron. </span>1993;<span class="ref-vol">65</span>:410–413.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8289991" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B2">2. <span class="citation">Ault A. FDA warns of potential protease-inhibitor link to hyperglycaemia. <span><span class="ref-journal">Lancet. </span>1997;<span class="ref-vol">349</span>:1819.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9269226" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B3">3. <span class="citation">Bertz R J, Granneman G R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. <span><span class="ref-journal">Clin Pharmacokinet. </span>1997;<span class="ref-vol">32</span>:210–258.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9084960" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B4">4. <span class="citation">Bogman K, Peyer A K, Torok M, Kusters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. <span><span class="ref-journal">Br J Pharmacol. </span>2001;<span class="ref-vol">132</span>:1183–1192.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572659/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11250868" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B5">5. <span class="citation">Boyd R A, Stern R H, Stewart B H, Wu X, Reyner E L, Zegarac E A, Randinitis E, Whitfield L. Atorvastatin coadministration may increase digoxin concentrations: inhibition of intestinal P-glycoprotein-mediated secretion. <span><span class="ref-journal">J Clin Pharmacol. </span>2000;<span class="ref-vol">40</span>:91–98.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10631627" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6">6. <span class="citation">Carpenter C C, Fischl M A, Hammer S M, Hirsch M S, Jacobsen D M, Katzenstein D A, Montaner J S, Richman D D, Saag M S, Schooley R T, Thompson M A, Vella S, Yeni P G, Volberding P A. Antiretroviral therapy for HIV-1 infection in 1998: updated recommendations of the International AIDS Society—USA Panel. <span><span class="ref-journal">JAMA. </span>1998;<span class="ref-vol">280</span>:78–86.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9660368" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7">7. <span class="citation">Cilla D D, Whifield L R, Gibson D M, Sedman A J, Posvar E. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy volunteers. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1996;<span class="ref-vol">60</span>:687–695.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8988072" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8">8. <span class="citation">Eastone J A, Decker C F. New-onset diabetes mellitus associated with use of protease inhibitor. <span><span class="ref-journal">Ann Intern Med. </span>1997;<span class="ref-vol">127</span>:947.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9382376" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9">9. <span class="citation">Gulick R M, Mellors J W, Havlir, D. D, Eron J J, Gonzalez C, McMahon D, Richman D D, Valentine F T, Jonas L, Meibohm A, Emini E A, Chodakewitz J A. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus and prior antiretroviral therapy. <span><span class="ref-journal">N Engl J Med. </span>1997;<span class="ref-vol">337</span>:734–739.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9287228" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10">10. <span class="citation">Kim R B, Fromm M F, Wandel C, Leake B, Wood A J J, Roden D M. The drug transporter P-glycoprotein limits oral absorption and brain entrance of HIV protease inhibitors. <span><span class="ref-journal">J Clin Investig. </span>1998;<span class="ref-vol">101</span>:289–294.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC508566/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9435299" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11">11. <span class="citation">Kliem V, Wanner C, Eisenhauer, T. T, Olbricht C J, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. <span><span class="ref-journal">Transplant Proc. </span>1996;<span class="ref-vol">28</span>:3126–3128.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8962211" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12">12. <span class="citation">Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. <span><span class="ref-journal">Clin Pharmacokinet. </span>1997;<span class="ref-vol">32</span>:403–425.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9160173" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13">13. <span class="citation">Miller K D, Jone E, Yanovski J A, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. <span><span class="ref-journal">Lancet. </span>1998;<span class="ref-vol">351</span>:871–875.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9525365" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14">14. <span class="citation">Mocroft A, Vella S, Benfield T L, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun J N, Phillips A N, Lundgren J D. Changing patterns of mortality across Europe in patients infected with HIV-1. <span><span class="ref-journal">Lancet. </span>1998;<span class="ref-vol">352</span>:1725–1730.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9848347" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15">15. <span class="citation">Murillas J, Martin T, Ramos A, Portero J L. Atorvastatin for protease inhibitor-related hyperlipidaemia. <span><span class="ref-journal">AIDS. </span>1999;<span class="ref-vol">13</span>:1424–1425.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10449305" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16">16. <span class="citation">Neuvonen P J, Jalava K M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1996;<span class="ref-vol">60</span>:54–61.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8689812" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17">17. <span class="citation">Neuvonen P J, Kantola T, Kivisto K T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1998;<span class="ref-vol">63</span>:332–341.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9542477" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B18">18. <span class="citation">Norman D J, Illingwoth D R, Munson J, Housenpud J. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin. <span><span class="ref-journal">N Engl J Med. </span>1988;<span class="ref-vol">318</span>:46–47.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/3275891" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19">19. <span class="citation">Palella F J, Delaney K M, Moorman A C, Loveless M O, Fuhrer J, Satten G A, Aschman D J, Holmberg S D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. <span><span class="ref-journal">N Engl J Med. </span>1998;<span class="ref-vol">338</span>:853–860.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9516219" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20">20. <span class="citation">Segaert M F, De Soete C, Vandewiele I, Verbanck J. Drug interaction-induced rhabdomyolysis. <span><span class="ref-journal">Nephrol Dial Transplant. </span>1996;<span class="ref-vol">11</span>:1846–1847.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8918636" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21">21. <span class="citation">Shaw A J, McLean K A, Evans B A. Disorder of fat distribution in HIV infection. <span><span class="ref-journal">Int J STD AIDS. </span>1998;<span class="ref-vol">9</span>:595–599.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9819110" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B22">22. <span class="citation">Torres R A, Barr M. Impact of combination therapy for HIV infection on inpatient census. <span><span class="ref-journal">N Engl J Med. </span>1997;<span class="ref-vol">336</span>:1531–1532.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9157292" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23">23. <span class="citation">Wang E, Casciano C N, Clement R P, Johnson W W. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. <span><span class="ref-journal">Pharmacol Sci. </span>2001;<span class="ref-vol">18</span>:800–806.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11474784" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B24">24. <span class="citation">Wu X, Whitfield L R, Stewart B H. Atorvastatin transport in Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. <span><span class="ref-journal">Pharmacol Sci. </span>2000;<span class="ref-vol">17</span>:209–215.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10751037" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B25">25. <span class="citation">Zhang K F, Wu E, Patick A K, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, Webber S. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. <span><span class="ref-journal">Antimicrob Agents Chemother. </span>2001;<span class="ref-vol">45</span>:1086–1093.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90428/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11257019" target="pmc_ext" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#__abstractid440270title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#__sec1title">MATERIALS AND METHODS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#__sec13title">RESULTS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#__sec17title">DISCUSSION</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#__ackid1089299title">ACKNOWLEDGMENTS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#__ref-listid1089309title">REFERENCES</a></li></ul></div></div><!--post-content--><hr class="whole_rhythm no_bottom_margin"><div class="courtesy-note no_margin small">Articles from <span class="acknowledgment-journal-title">Antimicrobial Agents and Chemotherapy</span> are provided here courtesy of <strong>American Society for Microbiology (ASM)</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/?report=reader"><img src="./PMC90851_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/pdf/ac1201003445.pdf">PDF (149K)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" data-citationid="PMC90851" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC90851%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC90851_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC90851%2F&amp;text=Pharmacokinetic%20Interactions%20between%20Nelfinavir%20and%203-Hydroxy-3-Methylglutaryl%20Coenzyme%20A%20Reductase%20Inhibitors%20Atorvastatin%20and%20Simvastatin" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC90851_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC90851%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC90851_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="11709322" data-aiid="90851" data-aid="90851" data-iid="2503" data-domainid="82" data-domain="aac" data-accid="PMC90851" data-md5="eee612011745a11179fdd39b204f9dbd">
<div class="portlet pubmed_favoritesad">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Save items</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="pmfavad" toggles="ui-portlet_content-21" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-21" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<input type="hidden" name="absid" id="absid" value="90851"><div id="pubmed_favoritesad" class="empty" data-db="pmc">
<span role="menubar"><div class="ui-ncbisetswitch ltd-hover" role="menuitem" aria-expanded="false" aria-haspopup="true"><a href="http://www.ncbi.nlm.nih.gov/myncbi/collections/" class="jig-ncbisetswitch blind collink ltd-hover ui-ncbisetswitch-hasStar" id="favList" data-jigconfig="destSelector:&#39;#favUL&#39;,starExists:true,createCollectionUrl:&#39;#&#39;,manageCollectionsUrl:&#39;/myncbi/collections/&#39;"><span class="star"></span>Add to Favorites</a><a class="ui-ncbisetswitch-button ltd-hover" title="View more options" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#"><span class="ui-icon ui-icon-triangle-1-s ui-ncbisetswitch-down">View more options</span></a></div></span><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu ui-ncbisetswitch-popper"><ul id="favUL" class="ui-ncbisetswitch-options"></ul><ul class="ui-ncbisetswitch-actions"><li class="ui-ncbisetswitch-actions-create" style="display: block;"><a class="ui-ncbisetswitch-create-collection" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#">Create collection...</a></li><li class="ui-ncbisetswitch-actions-manage" style="display: block;"><a class="ui-ncbisetswitch-manage-collections" href="http://www.ncbi.nlm.nih.gov/myncbi/collections/">Manage collections...</a></li></ul></div>
</div>
<div class="colloading">loading</div>
<span id="submenu_AddToCollections"><form method="post"><input type="submit" class="button_apply" name="addtocollection" value="1"></form></span>
</div></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" toggles="ui-portlet_content-23" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-23" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/15518608" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.</a><span class="source">[Am J Cardiol. 2004]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-25" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Jacobson TA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Cardiol. 2004 Nov 1; 94(9):1140-6. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/22922682" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.</a><span class="source">[Eur J Clin Pharmacol. 2013]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-27" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Teng R, Mitchell PD, Butler KA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Clin Pharmacol. 2013 Mar; 69(3):477-87. Epub 2012 Aug 25.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/15980690" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.</a><span class="source">[J Acquir Immune Defic Syndr. 2...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-29" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA, AIDS Clinical Trials Group A5108 Team. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Acquir Immune Defic Syndr. 2005 Jul 1; 39(3):307-12. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/14531725" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Clinical pharmacokinetics of atorvastatin.</a><span class="source">[Clin Pharmacokinet. 2003]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-31" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lennernäs H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Pharmacokinet. 2003; 42(13):1141-60. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/12405866" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.</a><span class="source">[Clin Pharmacokinet. 2002]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-33" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fichtenbaum CJ, Gerber JG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Pharmacokinet. 2002; 41(14):1195-211. </em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=11709322&amp;log%24=relatedreviews&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Reviews&amp;rendering-type=normal">See reviews...</a><a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=11709322&amp;log%24=relatedarticles&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Related%20Records&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Cited by other articles in PMC</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-35" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-35" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784685/" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis</a><span class="source">[AIDS care. 2015]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-37" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Okeke NL, Chin T, Clement M, Chow SC, Hicks CB. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">AIDS care. 2015 Oct 19; 28(4)475-482</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569258/" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes</a><span class="source">[PLoS ONE. 2015]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-39" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Korhonova M, Doricakova A, Dvorak Z. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PLoS ONE. 2015 Sep 14; 10(9)e0137720</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785656/" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population</a><span class="source">[Journal of General Internal Me...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-41" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Holtzman C, Armon C, Tedaldi E, Chmiel JS, Buchacz K, Wood K, Brooks JT, , and the HOPS Investigators. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Journal of General Internal Medicine. 2013 Apr 20; 28(10)1302-1310</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422541/" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Risk Assessment of Mechanism-Based Inactivation in Drug-Drug Interactions</a><span class="source">[Drug Metabolism and Dispositio...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-43" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fujioka Y, Kunze KL, Isoherranen N. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drug Metabolism and Disposition. 2012 Sep; 40(9)1653-1657</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371609/" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Management of the metabolic effects of HIV and HIV drugs</a><span class="source">[Nature Reviews. Endocrinology....]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-45" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brown TT, Glesby MJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Nature Reviews. Endocrinology. 2011 Sep 20; 8(1)11-21</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/citedby/" ref="reftype=relart&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|CitedBy&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Links</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-47" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-47" aria-hidden="false"><ul>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=90851" ref="reftype=Compound&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Compound</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-49" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Compound<div class="brieflinkpopdesc">PubChem Compound links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=medgen&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_medgen&amp;IdsFromResult=90851" ref="reftype=MedGen&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Unknown%20Link%20Name&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">MedGen</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-51" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">MedGen<div class="brieflinkpopdesc">Related information in MedGen</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/11709322/" ref="reftype=PubMed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">PubMed</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-53" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">PubMed<div class="brieflinkpopdesc">PubMed citations for these articles</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pcsubstance&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pcsubstance&amp;IdsFromResult=90851" ref="reftype=Substance&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Substance</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-55" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Substance<div class="brieflinkpopdesc">PubChem Substance links</div>
</div>
</li>
</ul></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Recent Activity</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" toggles="ui-portlet_content-57" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-57" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="">
<div class="action">
<a href="javascript:historyDisplayState(&#39;ClearHT&#39;)">Clear</a><a href="javascript:historyDisplayState(&#39;HTOff&#39;)" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState(&#39;HTOn&#39;)" class="HTOff">Turn On</a>
</div>
<ul id="activity">
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c261af2911de5257d465f">Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl C...</a><div class="ralinkpop offscreen_noflow">Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin<div class="brieflinkpopdesc">Antimicrobial Agents and Chemotherapy. 2001 Dec; 45(12)3445</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=2" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2618f0c03b7981753c95">PMC90851 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=3" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c25c97fd84438f0e9aaf9">Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegati...</a><div class="ralinkpop offscreen_noflow">Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108<div class="brieflinkpopdesc">NIHPA Author Manuscripts. 2006 Mar 21; 20(5)725</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=4" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c25c07fd84438f0e9a98d">1459289[uid] <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=5" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c241bf0c03b798174e93f">Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schi...</a><div class="ralinkpop offscreen_noflow">Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics<div class="brieflinkpopdesc">BMC Psychiatry. 2005; 5()26</div>
</div>
<div class="tertiary"></div>
</li>
</ul>
<p class="HTOn">Your browsing activity is empty.</p>
<p class="HTOff">Activity recording is turned off.</p>
<p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState(&#39;HTOn&#39;)">Turn recording back on</a></p>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity">See more...</a>
</div></div></div>
</div>
<div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p3" name="crb--__p3" rid="__p3" style="position: absolute; visibility: visible; width: 370px; top: 878px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-59"><ul>
<li class="two_line" reference_id="B6">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9660368/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.</a><span class="one_line_source">[JAMA.  1998]</span><div class="alt-note">
<div class="authors">Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA</div>
<div class="citation">JAMA. 1998 Jul 1; 280(1):78-86.</div>
</div>
</li>
<li class="two_line" reference_id="B9">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9287228/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.</a><span class="one_line_source">[N Engl J Med.  1997]</span><div class="alt-note">
<div class="authors">Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA</div>
<div class="citation">N Engl J Med. 1997 Sep 11; 337(11):734-9.</div>
</div>
</li>
<li class="two_line" reference_id="B22">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9157292/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Impact of combination therapy for HIV infection on inpatient census.</a><span class="one_line_source">[N Engl J Med.  1997]</span><div class="alt-note">
<div class="authors">Torres RA, Barr M</div>
<div class="citation">N Engl J Med. 1997 May 22; 336(21):1531-2.</div>
</div>
</li>
<li class="two_line" reference_id="B14">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9848347/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.</a><span class="one_line_source">[Lancet.  1998]</span><div class="alt-note">
<div class="authors">Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD</div>
<div class="citation">Lancet. 1998 Nov 28; 352(9142):1725-30.</div>
</div>
</li>
<li class="two_line" reference_id="B19">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9516219/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.</a><span class="one_line_source">[N Engl J Med.  1998]</span><div class="alt-note">
<div class="authors">Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD</div>
<div class="citation">N Engl J Med. 1998 Mar 26; 338(13):853-60.</div>
</div>
</li>
<li class="two_line" reference_id="B2" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9269226/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">FDA warns of potential protease-inhibitor link to hyperglycaemia.</a><span class="one_line_source">[Lancet.  1997]</span><div class="alt-note">
<div class="authors">Ault A</div>
<div class="citation">Lancet. 1997 Jun 21; 349(9068):1819.</div>
</div>
</li>
<li class="two_line" reference_id="B8" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9382376/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">New-onset diabetes mellitus associated with use of protease inhibitor.</a><span class="one_line_source">[Ann Intern Med.  1997]</span><div class="alt-note">
<div class="authors">Eastone JA, Decker CF</div>
<div class="citation">Ann Intern Med. 1997 Nov 15; 127(10):948.</div>
</div>
</li>
<li class="two_line" reference_id="B13" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9525365/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Visceral abdominal-fat accumulation associated with use of indinavir.</a><span class="one_line_source">[Lancet.  1998]</span><div class="alt-note">
<div class="authors">Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J</div>
<div class="citation">Lancet. 1998 Mar 21; 351(9106):871-5.</div>
</div>
</li>
<li class="two_line" reference_id="B21" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9819110/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Disorders of fat distribution in HIV infection.</a><span class="one_line_source">[Int J STD AIDS.  1998]</span><div class="alt-note">
<div class="authors">Shaw AJ, McLean KA, Evans BA</div>
<div class="citation">Int J STD AIDS. 1998 Oct; 9(10):595-9.</div>
</div>
</li>
<li class="two_line" reference_id="B15" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10449305/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Atorvastatin for protease inhibitor-related hyperlipidaemia.</a><span class="one_line_source">[AIDS.  1999]</span><div class="alt-note">
<div class="authors">Murillas J, Martín T, Ramos A, Portero JL</div>
<div class="citation">AIDS. 1999 Jul 30; 13(11):1424-5.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p4" name="crb--__p4" rid="__p4" style="position: absolute; visibility: visible; width: 370px; top: 1120px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-60"><ul>
<li class="two_line" reference_id="B16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8689812/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.</a><span class="one_line_source">[Clin Pharmacol Ther.  1996]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Jalava KM</div>
<div class="citation">Clin Pharmacol Ther. 1996 Jul; 60(1):54-61.</div>
</div>
</li>
<li class="two_line" reference_id="B17">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9542477/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.</a><span class="one_line_source">[Clin Pharmacol Ther.  1998]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Kantola T, Kivistö KT</div>
<div class="citation">Clin Pharmacol Ther. 1998 Mar; 63(3):332-41.</div>
</div>
</li>
<li class="two_line" reference_id="B1">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8289991/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.</a><span class="one_line_source">[Nephron.  1993]</span><div class="alt-note">
<div class="authors">Arnadottir M, Eriksson LO, Thysell H, Karkas JD</div>
<div class="citation">Nephron. 1993; 65(3):410-3.</div>
</div>
</li>
<li class="two_line" reference_id="B11">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8962211/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine.</a><span class="one_line_source">[Transplant Proc.  1996]</span><div class="alt-note">
<div class="authors">Kliem V, Wanner C, Eisenhauer T, Olbricht CJ, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U</div>
<div class="citation">Transplant Proc. 1996 Dec; 28(6):3126-8.</div>
</div>
</li>
<li class="two_line" reference_id="B18" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/3275891/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.</a><span class="one_line_source">[N Engl J Med.  1988]</span><div class="alt-note">
<div class="authors">Norman DJ, Illingworth DR, Munson J, Hosenpud J</div>
<div class="citation">N Engl J Med. 1988 Jan 7; 318(1):46-7.</div>
</div>
</li>
<li class="two_line" reference_id="B20" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8918636/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Drug-interaction-induced rhabdomyolysis.</a><span class="one_line_source">[Nephrol Dial Transplant.  1996]</span><div class="alt-note">
<div class="authors">Segaert MF, De Soete C, Vandewiele I, Verbanck J</div>
<div class="citation">Nephrol Dial Transplant. 1996 Sep; 11(9):1846-7.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p13" name="crb--__p13" rid="__p13" style="position: absolute; visibility: visible; width: 370px; top: 2123px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-61"><ul><li class="two_line" reference_id="B25">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11257019/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.</a><span class="one_line_source">[Antimicrob Agents Chemother.  2001]</span><div class="alt-note">
<div class="authors">Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, Webber S</div>
<div class="citation">Antimicrob Agents Chemother. 2001 Apr; 45(4):1086-93.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p14" name="crb--__p14" rid="__p14" style="position: absolute; visibility: visible; width: 370px; top: 2516px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-62"><ul><li class="two_line" reference_id="B7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8988072/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.</a><span class="one_line_source">[Clin Pharmacol Ther.  1996]</span><div class="alt-note">
<div class="authors">Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL</div>
<div class="citation">Clin Pharmacol Ther. 1996 Dec; 60(6):687-95.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p25" name="crb--__p25" rid="__p25" style="position: absolute; visibility: visible; width: 370px; top: 5253px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-63"><ul>
<li class="two_line" reference_id="B16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/8689812/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.</a><span class="one_line_source">[Clin Pharmacol Ther.  1996]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Jalava KM</div>
<div class="citation">Clin Pharmacol Ther. 1996 Jul; 60(1):54-61.</div>
</div>
</li>
<li class="two_line" reference_id="B17">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9542477/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.</a><span class="one_line_source">[Clin Pharmacol Ther.  1998]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Kantola T, Kivistö KT</div>
<div class="citation">Clin Pharmacol Ther. 1998 Mar; 63(3):332-41.</div>
</div>
</li>
<li class="two_line" reference_id="B3">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9084960/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.</a><span class="one_line_source">[Clin Pharmacokinet.  1997]</span><div class="alt-note">
<div class="authors">Bertz RJ, Granneman GR</div>
<div class="citation">Clin Pharmacokinet. 1997 Mar; 32(3):210-58.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p26" name="crb--__p26" rid="__p26" style="position: absolute; visibility: visible; width: 370px; top: 5986px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-64"><ul>
<li class="two_line" reference_id="B4">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11250868/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">HMG-CoA reductase inhibitors and P-glycoprotein modulation.</a><span class="one_line_source">[Br J Pharmacol.  2001]</span><div class="alt-note">
<div class="authors">Bogman K, Peyer AK, Török M, Küsters E, Drewe J</div>
<div class="citation">Br J Pharmacol. 2001 Mar; 132(6):1183-92.</div>
</div>
</li>
<li class="two_line" reference_id="B10">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/9435299/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.</a><span class="one_line_source">[J Clin Invest.  1998]</span><div class="alt-note">
<div class="authors">Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR</div>
<div class="citation">J Clin Invest. 1998 Jan 15; 101(2):289-94.</div>
</div>
</li>
<li class="two_line" reference_id="B23">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11474784/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.</a><span class="one_line_source">[Pharm Res.  2001]</span><div class="alt-note">
<div class="authors">Wang E, Casciano CN, Clement RP, Johnson WW</div>
<div class="citation">Pharm Res. 2001 Jun; 18(6):800-6.</div>
</div>
</li>
<li class="two_line" reference_id="B24">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10751037/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.</a><span class="one_line_source">[Pharm Res.  2000]</span><div class="alt-note">
<div class="authors">Wu X, Whitfield LR, Stewart BH</div>
<div class="citation">Pharm Res. 2000 Feb; 17(2):209-15.</div>
</div>
</li>
<li class="two_line" reference_id="B5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10631627/" ref="reftype=pubmed&amp;article-id=90851&amp;issue-id=2503&amp;journal-id=82&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.</a><span class="one_line_source">[J Clin Pharmacol.  2000]</span><div class="alt-note">
<div class="authors">Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L</div>
<div class="citation">J Clin Pharmacol. 2000 Jan; 40(1):91-8.</div>
</div>
</li>
</ul></div>
</div>
</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC90851_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-B6" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.<div class="authors">Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA</div><div class="citation">JAMA. 1998 Jul 1; 280(1):78-86.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9660368/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B6">Ref list</a>]</p></div><div id="body-link-popper-B9" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.<div class="authors">Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA</div><div class="citation">N Engl J Med. 1997 Sep 11; 337(11):734-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9287228/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B9">Ref list</a>]</p></div><div id="body-link-popper-B22" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Impact of combination therapy for HIV infection on inpatient census.<div class="authors">Torres RA, Barr M</div><div class="citation">N Engl J Med. 1997 May 22; 336(21):1531-2.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9157292/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B22">Ref list</a>]</p></div><div id="body-link-popper-B14" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.<div class="authors">Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD</div><div class="citation">Lancet. 1998 Nov 28; 352(9142):1725-30.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9848347/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B14">Ref list</a>]</p></div><div id="body-link-popper-B19" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.<div class="authors">Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD</div><div class="citation">N Engl J Med. 1998 Mar 26; 338(13):853-60.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9516219/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B19">Ref list</a>]</p></div><div id="body-link-popper-B2" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">FDA warns of potential protease-inhibitor link to hyperglycaemia.<div class="authors">Ault A</div><div class="citation">Lancet. 1997 Jun 21; 349(9068):1819.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9269226/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B2">Ref list</a>]</p></div><div id="body-link-popper-B8" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">New-onset diabetes mellitus associated with use of protease inhibitor.<div class="authors">Eastone JA, Decker CF</div><div class="citation">Ann Intern Med. 1997 Nov 15; 127(10):948.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9382376/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B8">Ref list</a>]</p></div><div id="body-link-popper-B13" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Visceral abdominal-fat accumulation associated with use of indinavir.<div class="authors">Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J</div><div class="citation">Lancet. 1998 Mar 21; 351(9106):871-5.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9525365/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B13">Ref list</a>]</p></div><div id="body-link-popper-B21" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Disorders of fat distribution in HIV infection.<div class="authors">Shaw AJ, McLean KA, Evans BA</div><div class="citation">Int J STD AIDS. 1998 Oct; 9(10):595-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9819110/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B21">Ref list</a>]</p></div><div id="body-link-popper-B15" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Atorvastatin for protease inhibitor-related hyperlipidaemia.<div class="authors">Murillas J, Martín T, Ramos A, Portero JL</div><div class="citation">AIDS. 1999 Jul 30; 13(11):1424-5.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10449305/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B15">Ref list</a>]</p></div><div id="body-link-popper-B16" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.<div class="authors">Neuvonen PJ, Jalava KM</div><div class="citation">Clin Pharmacol Ther. 1996 Jul; 60(1):54-61.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8689812/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B16">Ref list</a>]</p></div><div id="body-link-popper-B17" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.<div class="authors">Neuvonen PJ, Kantola T, Kivistö KT</div><div class="citation">Clin Pharmacol Ther. 1998 Mar; 63(3):332-41.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9542477/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B17">Ref list</a>]</p></div><div id="body-link-popper-B1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.<div class="authors">Arnadottir M, Eriksson LO, Thysell H, Karkas JD</div><div class="citation">Nephron. 1993; 65(3):410-3.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8289991/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B1">Ref list</a>]</p></div><div id="body-link-popper-B11" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine.<div class="authors">Kliem V, Wanner C, Eisenhauer T, Olbricht CJ, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U</div><div class="citation">Transplant Proc. 1996 Dec; 28(6):3126-8.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8962211/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B11">Ref list</a>]</p></div><div id="body-link-popper-B18" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.<div class="authors">Norman DJ, Illingworth DR, Munson J, Hosenpud J</div><div class="citation">N Engl J Med. 1988 Jan 7; 318(1):46-7.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/3275891/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B18">Ref list</a>]</p></div><div id="body-link-popper-B20" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Drug-interaction-induced rhabdomyolysis.<div class="authors">Segaert MF, De Soete C, Vandewiele I, Verbanck J</div><div class="citation">Nephrol Dial Transplant. 1996 Sep; 11(9):1846-7.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8918636/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B20">Ref list</a>]</p></div><div id="body-link-popper-B25" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.<div class="authors">Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, Webber S</div><div class="citation">Antimicrob Agents Chemother. 2001 Apr; 45(4):1086-93.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11257019/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B25">Ref list</a>]</p></div><div id="body-link-popper-B7" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.<div class="authors">Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL</div><div class="citation">Clin Pharmacol Ther. 1996 Dec; 60(6):687-95.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8988072/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B7">Ref list</a>]</p></div><div id="body-link-popper-B3" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.<div class="authors">Bertz RJ, Granneman GR</div><div class="citation">Clin Pharmacokinet. 1997 Mar; 32(3):210-58.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9084960/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B3">Ref list</a>]</p></div><div id="body-link-popper-B4" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">HMG-CoA reductase inhibitors and P-glycoprotein modulation.<div class="authors">Bogman K, Peyer AK, Török M, Küsters E, Drewe J</div><div class="citation">Br J Pharmacol. 2001 Mar; 132(6):1183-92.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11250868/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B4">Ref list</a>]</p></div><div id="body-link-popper-B10" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.<div class="authors">Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR</div><div class="citation">J Clin Invest. 1998 Jan 15; 101(2):289-94.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9435299/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B10">Ref list</a>]</p></div><div id="body-link-popper-B23" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.<div class="authors">Wang E, Casciano CN, Clement RP, Johnson WW</div><div class="citation">Pharm Res. 2001 Jun; 18(6):800-6.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11474784/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B23">Ref list</a>]</p></div><div id="body-link-popper-B24" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.<div class="authors">Wu X, Whitfield LR, Stewart BH</div><div class="citation">Pharm Res. 2000 Feb; 17(2):209-15.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10751037/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B24">Ref list</a>]</p></div><div id="body-link-popper-B5" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.<div class="authors">Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L</div><div class="citation">J Clin Pharmacol. 2000 Jan; 40(1):91-8.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10631627/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#B5">Ref list</a>]</p></div></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:10:34-04:00&amp;Host=ptpmc201">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC90851_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC90851_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC90851_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90851/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=aac&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC90851/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc201 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC90851_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul></body></html>